Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled. Original design: To determine whether the experimental drug recombinant CD4 (rCD4), which is produced through genetic engineering technology, is safe and well-tolerated in children infected with or at risk for HIV infection.

rCD4 may be an effective treatment for HIV infection, based on its ability to block infection of human cells by HIV in laboratory tests. However, the activity of rCD4 still needs to be confirmed in clinical trials. It is hoped that these tests will show that rCD4 is both safe and effective in treating children who are infected with or who are at risk for infection with HIV.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

rCD4 may be an effective treatment for HIV infection, based on its ability to block infection of human cells by HIV in laboratory tests. However, the activity of rCD4 still needs to be confirmed in clinical trials. It is hoped that these tests will show that rCD4 is both safe and effective in treating children who are infected with or who are at risk for infection with HIV.

Children have preliminary testing and evaluation to determine eligibility and health. The dosage schedule varies with the dose. During the course of the study, children are monitored for safety through physical exams and blood tests. They have blood withdrawn to study the response to rCD4 and measure the activity of rCD4 in the body. Children may receive immunization of DPT (diphtheria, pertussis, tetanus) or DT and a polio vaccine to measure their antibody response. If the rCD4 is beneficial, children may continue treatment. The study is conducted in four parts:

  • Part A: Children 13 to 18 years old.
  • Part B: Children 3 months to less than 13 years old.
  • Part C: Full-term infants over 3 months old.
  • Part D: Preterm infants less than 3 months old. Parts C and D are not started until parts A and B have been completed.

Tipo de estudio

Intervencionista

Inscripción

40

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • San Francisco, California, Estados Unidos, 94143
        • Northern California Pediatric AIDS Treatment Ctr / UCSF
      • Stanford, California, Estados Unidos, 943054149
        • Stanford Univ School of Medicine / Pediatrics
    • Illinois
      • Chicago, Illinois, Estados Unidos, 606143394
        • Chicago Children's Memorial Hosp
      • Chicago, Illinois, Estados Unidos, 60614
        • Children's Memorial Med Ctr
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 071072198
        • Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 277103499
        • Duke Univ Med Ctr

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 día a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Prophylactic medication for patients with previous documented episodes of Pneumocystis carinii pneumonia (PCP).
  • Concomitant zidovudine (AZT) or intravenous gamma globulin (IVIG) during maintenance therapy phase of the study.

AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled.

Original design: Patients must be infected with HIV or at risk for HIV infection. They must be one of the following:

  • Asymptomatic.
  • Mildly symptomatic but not eligible for and/or decline ACTG protocol 052.
  • Markedly symptomatic but not eligible for and/or decline ACTG protocol 051 or cannot tolerate zidovudine (AZT) therapy.

All patients must have:

  • A life expectancy of at least 3 months.
  • A legally-qualified guardian with the ability to sign a written informed consent form, which must be obtained prior to treatment. A willingness to abstain from all other experimental therapy for HIV infection during the entire study period.

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Zidovudine (AZT).
  • Intravenous gamma globulin (IVIG).
  • Pentamidine.
  • Trimethoprim / sulfamethoxazole (TMP/SMX).
  • Corticosteroids.
  • Nonsteroidal anti-inflammatory agents (NSAIDS).
  • Other known immunomodulatory agents.
  • All other experimental therapies.

Patients will be excluded from the study for the following reasons:

  • Serious active opportunistic infection or malignancies prior to study entry.
  • Defined organ insufficiencies.

Prior Medication:

Excluded within 3 weeks of study entry:

  • Zidovudine (AZT).
  • Intravenous gamma globulin.
  • Cancer chemotherapy.
  • Immunomodulatory agents.
  • Other experimental therapy.

Patients may not have any of the following diseases or symptoms:

  • Serious active opportunistic infection or malignancies prior to study entry.
  • Cardiopathy.
  • Two or more episodes of prior Pneumocystis carinii pneumonia (PCP).
  • Hematologic insufficiency defined as granulocytes = or < 1000 cells/mm3; platelets = or < 100000 cells/mm3; hemoglobin = or < 8 g/dl.
  • Renal insufficiency defined as creatinine > 2 mg/dl; = or > 5 white blood cells or red blood cells/hpf or = or > 2+ proteinuria in urine.
  • Hepatic insufficiency defined as bilirubin = or > 3 x upper limit of normal; SGOT = or > 10 upper limit of normal.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Enmascaramiento: Ninguno (etiqueta abierta)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Silla de estudio: P Weintrub

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

  • Weintrub P, Yogev R, Conner E, Wilfert K, Mordenti J, Ammann AJ. Safety and pharmacokinetics of recombinant CD4 in children with HIV infection. Int Conf AIDS. 1990 Jun 20-23;6(2):95 (abstract no FB23)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas de registro del estudio

Enviado por primera vez

2 de noviembre de 1999

Primero enviado que cumplió con los criterios de control de calidad

30 de agosto de 2001

Publicado por primera vez (Estimar)

31 de agosto de 2001

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

24 de junio de 2005

Última actualización enviada que cumplió con los criterios de control de calidad

23 de junio de 2005

Última verificación

1 de octubre de 1996

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Infecciones por VIH

Ensayos clínicos sobre Antígenos CD4

3
Suscribir